Skip to main content
Top
Published in: Digestive Diseases and Sciences 12/2014

01-12-2014 | Original Article

Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease

Authors: Sang Bong Ahn, Kiseok Jang, Dae Won Jun, Byung Hoon Lee, Kye Jung Shin

Published in: Digestive Diseases and Sciences | Issue 12/2014

Login to get access

Abstract

Background

Liver X receptor (LXR) is an oxysterol-activated nuclear receptor involved in the control of major metabolic pathways for cholesterol homeostasis and lipogenesis. Although the role of LXR in hepatic steatosis is well known, its correlation with intrahepatic inflammation and fibrosis has not been thoroughly studied. We investigated the association between LXRα, hepatic inflammation, and fibrosis, as well as its correlation with other intrahepatic lipid transporters in patients with nonalcoholic fatty liver disease (NAFLD).

Methods

We evaluated clinical characteristics including sex, age, body mass index, and laboratory findings from 40 NAFLD and 16 control patients. Immunohistochemical staining was carried out on liver biopsy samples from all patients.

Results

The positive rate of LXRα expression was 30 % in the control group, 50 % in the NAFLD group, and 97 % in NASH groups. LXRα expression was positively correlated with not only the amount of intrahepatic fat, but also with intrahepatic inflammation and hepatic fibrosis. LXRα expression showed positive correlation with intrahepatic expression of ABCG5/8, CD36, and SREBP-1c. The expression of ABCA1, ABCG5/8, SREBP-1c, and CD36 was higher in NAFLD than in controls and there was no further increase in the NASH group. NPC1L1 was abundant in human liver. Expression of NPC1L1 was negatively correlated with intrahepatic inflammation and LXRα intensity.

Conclusion

LXR expression correlated with the degree of hepatic fat deposition, as well as with hepatic inflammation and fibrosis in NAFLD patients. Our research suggests that LXR is an attractive target for treatment and regulation of hepatic inflammation and fibrosis.
Appendix
Available only for authorised users
Literature
1.
go back to reference Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996;383:728–731.PubMedCrossRef Janowski BA, Willy PJ, Devi TR, Falck JR, Mangelsdorf DJ. An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996;383:728–731.PubMedCrossRef
2.
go back to reference Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008;134:556–567.PubMedCrossRef Zhou J, Febbraio M, Wada T, et al. Hepatic fatty acid transporter Cd36 is a common target of LXR, PXR, and PPARgamma in promoting steatosis. Gastroenterology. 2008;134:556–567.PubMedCrossRef
3.
go back to reference Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459–481.PubMedCrossRef Repa JJ, Mangelsdorf DJ. The role of orphan nuclear receptors in the regulation of cholesterol homeostasis. Annu Rev Cell Dev Biol. 2000;16:459–481.PubMedCrossRef
4.
go back to reference Wouters K, van Bilsen M, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of nonalcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 2010;584:1001–1005.PubMedCrossRef Wouters K, van Bilsen M, van Gorp PJ, et al. Intrahepatic cholesterol influences progression, inhibition and reversal of nonalcoholic steatohepatitis in hyperlipidemic mice. FEBS Lett. 2010;584:1001–1005.PubMedCrossRef
5.
go back to reference Grefhorst A, van Dijk TH, Hammer A, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab. 2005;289:E829–E838.PubMedCrossRef Grefhorst A, van Dijk TH, Hammer A, et al. Differential effects of pharmacological liver X receptor activation on hepatic and peripheral insulin sensitivity in lean and ob/ob mice. Am J Physiol Endocrinol Metab. 2005;289:E829–E838.PubMedCrossRef
6.
go back to reference Liu Y, Han X, Bian Z, et al. Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:390–398.PubMedCrossRef Liu Y, Han X, Bian Z, et al. Activation of liver X receptors attenuates endotoxin-induced liver injury in mice with nonalcoholic fatty liver disease. Dig Dis Sci. 2012;57:390–398.PubMedCrossRef
7.
go back to reference Wang YY, Dahle MK, Agren J, et al. Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock. 2006;25:141–146.PubMedCrossRef Wang YY, Dahle MK, Agren J, et al. Activation of the liver X receptor protects against hepatic injury in endotoxemia by suppressing Kupffer cell activation. Shock. 2006;25:141–146.PubMedCrossRef
8.
go back to reference Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366–1374.PubMedCrossRef Yamaguchi K, Yang L, McCall S, et al. Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis. Hepatology. 2007;45:1366–1374.PubMedCrossRef
9.
go back to reference Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.PubMedCrossRef Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology. 2005;41:1313–1321.PubMedCrossRef
10.
go back to reference Fridman E, Daya D, Srigley J, Whelan KF, Lu JP, Pinthus JH. Construction of tissue micro array from prostate needle biopsies using the vertical clustering re-arrangement technique. Prostate. 2011;71:1374–1381.PubMedCrossRef Fridman E, Daya D, Srigley J, Whelan KF, Lu JP, Pinthus JH. Construction of tissue micro array from prostate needle biopsies using the vertical clustering re-arrangement technique. Prostate. 2011;71:1374–1381.PubMedCrossRef
11.
go back to reference Obermann EC, Marienhagen J, Stoehr R, Wuensch PH, Hofstaedter F (2005) Tissue microarray construction from bone marrow biopsies. BioTechniques. 39:822, 824, 826. Obermann EC, Marienhagen J, Stoehr R, Wuensch PH, Hofstaedter F (2005) Tissue microarray construction from bone marrow biopsies. BioTechniques. 39:822, 824, 826.
12.
go back to reference Viennois E, Pommier AJ, Mouzat K, et al. Targeting liver X receptors in human health: deadlock or promising trail? Expert Opin Ther Targets. 2011;15:219–232.PubMedCrossRef Viennois E, Pommier AJ, Mouzat K, et al. Targeting liver X receptors in human health: deadlock or promising trail? Expert Opin Ther Targets. 2011;15:219–232.PubMedCrossRef
13.
go back to reference Beaven SW, Matveyenko A, Wroblewski K, et al. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab. 2013;18:106–117.PubMedCentralPubMedCrossRef Beaven SW, Matveyenko A, Wroblewski K, et al. Reciprocal regulation of hepatic and adipose lipogenesis by liver X receptors in obesity and insulin resistance. Cell Metab. 2013;18:106–117.PubMedCentralPubMedCrossRef
14.
go back to reference Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213–219.PubMedCrossRef Joseph SB, Castrillo A, Laffitte BA, Mangelsdorf DJ, Tontonoz P. Reciprocal regulation of inflammation and lipid metabolism by liver X receptors. Nat Med. 2003;9:213–219.PubMedCrossRef
15.
go back to reference Beaven SW, Wroblewski K, Wang J, et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology. 2011;140:1052–1062.PubMedCentralPubMedCrossRef Beaven SW, Wroblewski K, Wang J, et al. Liver X receptor signaling is a determinant of stellate cell activation and susceptibility to fibrotic liver disease. Gastroenterology. 2011;140:1052–1062.PubMedCentralPubMedCrossRef
16.
go back to reference Lund EG, Peterson LB, Adams AD, et al. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol. 2006;71:453–463.PubMedCrossRef Lund EG, Peterson LB, Adams AD, et al. Different roles of liver X receptor alpha and beta in lipid metabolism: effects of an alpha-selective and a dual agonist in mice deficient in each subtype. Biochem Pharmacol. 2006;71:453–463.PubMedCrossRef
17.
go back to reference Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113:90–97.PubMedCrossRef Naik SU, Wang X, Da Silva JS, et al. Pharmacological activation of liver X receptors promotes reverse cholesterol transport in vivo. Circulation. 2006;113:90–97.PubMedCrossRef
18.
go back to reference Jiang ZY, Parini P, Eggertsen G, et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res. 2008;49:464–472.PubMedCrossRef Jiang ZY, Parini P, Eggertsen G, et al. Increased expression of LXR alpha, ABCG5, ABCG8, and SR-BI in the liver from normolipidemic, nonobese Chinese gallstone patients. J Lipid Res. 2008;49:464–472.PubMedCrossRef
19.
go back to reference Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968–1978.PubMedCentralPubMedCrossRef Temel RE, Tang W, Ma Y, et al. Hepatic Niemann-Pick C1-like 1 regulates biliary cholesterol concentration and is a target of ezetimibe. J Clin Invest. 2007;117:1968–1978.PubMedCentralPubMedCrossRef
20.
go back to reference Jia L, Ma Y, Rong S, et al. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res. 2010;51:3135–3144.PubMedCentralPubMedCrossRef Jia L, Ma Y, Rong S, et al. Niemann-Pick C1-Like 1 deletion in mice prevents high-fat diet-induced fatty liver by reducing lipogenesis. J Lipid Res. 2010;51:3135–3144.PubMedCentralPubMedCrossRef
21.
go back to reference Ducheix S, Montagner A, Polizzi A, et al. Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. J Hepatol. 2013;58:984–992.PubMedCrossRef Ducheix S, Montagner A, Polizzi A, et al. Essential fatty acids deficiency promotes lipogenic gene expression and hepatic steatosis through the liver X receptor. J Hepatol. 2013;58:984–992.PubMedCrossRef
Metadata
Title
Expression of Liver X Receptor Correlates with Intrahepatic Inflammation and Fibrosis in Patients with Nonalcoholic Fatty Liver Disease
Authors
Sang Bong Ahn
Kiseok Jang
Dae Won Jun
Byung Hoon Lee
Kye Jung Shin
Publication date
01-12-2014
Publisher
Springer US
Published in
Digestive Diseases and Sciences / Issue 12/2014
Print ISSN: 0163-2116
Electronic ISSN: 1573-2568
DOI
https://doi.org/10.1007/s10620-014-3289-x

Other articles of this Issue 12/2014

Digestive Diseases and Sciences 12/2014 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.